Clinical Trials in Suining Shi, China
1 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 3
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Breast Cancer
AstraZeneca300 enrolled82 locationsNCT06635447
Recruiting
Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
AstraZeneca5,500 enrolled794 locationsNCT05952557